Aug 31, 2022 / 12:30PM GMT
Operator
Good day, and thank you for standing by. Welcome to the Aquestive Therapeutics business update. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Bennett Watson of ICR Westwicke Investor Relations. Please go ahead.
Bennett Watson -
Thank you, operator. Good morning, and welcome to today's call. I'm joined by Dan Barber, Chief Executive Officer, who is going to provide an overview of recent business developments. The company's remarks today correspond with the press release issued before market opened today, and the Form 8-K that was filed this morning with the Securities and Exchange Commission concerning the business developments we will be discussing today.
Before we begin, let me remind you that today's call will include forward-looking statements based on the company's current expectations. These statements reflect our judgment as of today only and are subject to risks and uncertainties that could cause actual results to differ materially from
Aquestive Therapeutics Receives FDA Tentative Approval for Libervant™ (diazepam) Buccal Film Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot